1. Trevi Therapeutics is developing Haduvio for chronic cough treatment. 2. Senior management will present at three investor conferences in March. 3. Chronic cough significantly affects quality of life for IPF patients. 4. No approved therapies currently exist for chronic cough or RCC. 5. Haduvio's safety and efficacy remain unverified by regulatory authorities.
The upcoming presentations may attract investor interest, potentially boosting TRVI's stock. Historical examples show presentation announcements can significantly influence stock dynamics, especially in clinical-stage biotech.
The article highlights key events that could influence TRVI's visibility with investors, crucial for a clinical-stage company.
The immediate upcoming conferences may lead to a short-term price fluctuation as investor reactions unfold post-presentations.
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor conferences in March.
March 3-5, 2025, Boston, Massachusetts
Corporate Presentation: March 4, 10:30-11:00am ET
Trevi Representatives: Lisa Delfini, Chief Financial Officer, and Farrell Simon, Chief Commercial Officer
A Corporate presentation is available for in-person conference attendees.
March 10-12, 2025, Miami, Florida
Corporate Presentation: March 12, 8:00am ET
Trevi Representatives: Jennifer Good, President and CEO, and James Cassella, Chief Development Officer
A Corporate presentation is available for in-person conference attendees.
March 23-26, 2025, Jackson Hole, Wyoming
Trevi Representative: Lisa Delfini, Chief Financial Officer
A Corporate presentation is available for in-person conference attendees.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that play a key role in controlling cough hypersensitivity. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.
Chronic cough is highly prevalent in IPF patients, impacting up to 85% of the IPF population. There are ~140,000 U.S. IPF patients and the impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients.
Refractory chronic cough affects approximately 2-3 million adults in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly disruptive disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them. There are also no approved therapies for RCC in the U.S.
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
info@trevitherapeutics.com
Rosalia Scampoli
914-815-1465
media@trevitherapeutics.com
SOURCE Trevi Therapeutics, Inc.